The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
To assess the effects of deferoxamine (DFO) on the kidneys, we studied 27 patients with thalassemia major on chronic subcutaneous (s.c.) DFO therapy. In 41% of the patients glomerular filtration rate (GFR) values were above the normal range. In a previous study similar findings were reported for thalassemia patients who did not receive DFO. The subcutaneous administration of DFO was associated with a clinically significant decrease in GFR in 40% of the patients and in a mild decrease in another 40%. In all cases of severe decreases in GFR, it tended to return to baseline values upon discontinuation of DFO. There was a significant increase in urine volume during DFO therapy. These changes are consistent with our previous observation in humans and dogs receiving high dose i.v. DFO, albeit milder.
Koren
G
G
Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, Canada.
Kochavi-Atiya
Y
Y
Bentur
Y
Y
Olivieri
N F
NF
D000293:Adolescent; D000328:Adult; D002648:Child; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D013789:Thalassemia / Q000188:drug therapy*
D003676:Deferoxamine